Business
15 Advantages of Our Platform We are using our GeneTAC ® platform to develop small molecule genomic medicine candidates that are designed to offer precise modulation of gene transcription.
Design Therapeutics, Inc.: Revenue grew to $0 from $0. Net loss widened to $69.79M from $49.59M. Free cash flow outflow widened to $54.55M from $43.45M. Net margin was unavailable and was not inferred. Design Therapeutics, Inc.'s principal statistical and annual-change screens add no overriding warning to the reported profit and cash-flow record.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew to $0 from $0OK
- Profitability — Net loss widened to $69.79M from $49.59MWatch
- Cash flow — Free cash flow outflow widened to $54.55M from $43.45MWatch
- Margins — Net margin was unavailable and was not inferredNote
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 1 saleWatch
Leadership changes
From Design Therapeutics, Inc.'s own filings, the day they're filed.
- David Shapiro · director · appointmenteff. 2026-03-31
- Deepa Prasad · Directors · appointmenteff. 2026-02-01
- Justin Gover · director · appointmenteff. 2025-09-09
Latest filings
- 10-Q · Quarterly report2026-08-03
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-05-18
- 8-K · Company announcement2026-04-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Design Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.